Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 18/20 | 0.61 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4712636 | 0.90 | MAPK8 (0.53) | MAPK8DPP4 | |
| SCHEMBL4713109 | 0.87 | MAPK8 (0.58) | MAPK8DPP4 | |
| SCHEMBL4711018 | 0.87 | MAPK8 (0.60) | MAPK8MAPK9MAPK10 | |
| SCHEMBL4711184 | 0.87 | MAPK8 (0.62) | MAPK8PLA2G2ADPP4 | |
| SCHEMBL4709619 | 0.85 | MAPK8 (0.56) | MAPK8DPP4 | |
| SCHEMBL4712904 | 0.85 | MAPK8 (0.60) | MAPK8PLA2G2ADPP4MAPK9MAPK10 | |
| SCHEMBL4713524 | 0.84 | MAPK8 (0.59) | MAPK8PLA2G2ADPP4MAPK9MAPK10 | |
| SCHEMBL4709304 | 0.84 | MAPK8 (0.70) | MAPK8DPP4MAPK9MAPK10 | |
| SCHEMBL4712288 | 0.83 | MAPK8 (0.61) | MAPK8PLA2G2AMAPK9MAPK10 | |
| SCHEMBL4711159 | 0.82 | MAPK8 (0.60) | MAPK8DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402595-B2 | Enzyme inhibitors with isoquinolinone structures | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-22 | — | — | US | disclosed |
| US-20050148624-A1 | Jnk inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1484320-A1 | JNK INHIBITOR | Takeda Chemical Industries, Ltd. (JP) | 2004-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148624-A1 | Jnk inhibitor | MAPK3, MAPKAPK3, MAPK1 | MAPK8 5/4885PLA2G2A 4560/4885DPP4 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.